Aprepitant

Generic Name
Aprepitant
Brand Names
Aponvie, Cinvanti, Emend
Drug Type
Small Molecule
Chemical Formula
C23H21F7N4O3
CAS Number
170729-80-3
Unique Ingredient Identifier
1NF15YR6UY
Background

Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substan...

Indication

For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).

Associated Conditions
Chemotherapy-Induced Nausea and Vomiting, Post Operative Nausea and Vomiting (PONV), Acute delayed Nausea caused by highly emetogenic cancer chemotherapy
Associated Therapies
-
Clinical Trials
Related News

A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)

First Posted Date
2012-11-22
Last Posted Date
2018-09-25
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
229
Registration Number
NCT01732458

Aprepitant in the Management of Biological Therapies-related Severe Pruritus

Phase 2
Completed
Conditions
ITCH
Interventions
Drug: Aprepitant
Drug: Prednisone
Drug: Fexofenadine
First Posted Date
2012-09-12
Last Posted Date
2012-09-12
Lead Sponsor
Campus Bio-Medico University
Target Recruit Count
45
Registration Number
NCT01683552
Locations
🇮🇹

Campus Bio-Medico of Rome University, Roma, Italy

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

First Posted Date
2012-07-13
Last Posted Date
2013-11-07
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
40
Registration Number
NCT01640340
Locations
🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

First Posted Date
2012-07-10
Last Posted Date
2018-09-25
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
494
Registration Number
NCT01636947

Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome

Phase 4
Terminated
Conditions
Pruritus
Sezary Syndrome
Interventions
Drug: Aprepitant
Drug: Placebo
First Posted Date
2012-06-21
Last Posted Date
2017-05-10
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
7
Registration Number
NCT01625455
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Treatment for Cannabis Withdrawal and Dependence

First Posted Date
2012-06-05
Last Posted Date
2017-05-01
Lead Sponsor
The Scripps Research Institute
Target Recruit Count
70
Registration Number
NCT01611948
Locations
🇺🇸

The Scripps Research Institute, La Jolla, California, United States

The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing

Not Applicable
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Drug: placebo
Drug: aprepitant
First Posted Date
2012-04-19
Last Posted Date
2013-07-19
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
16
Registration Number
NCT01580423
Locations
🇺🇸

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

First Posted Date
2012-02-17
Last Posted Date
2018-08-15
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
22
Registration Number
NCT01534637
Locations
🇺🇸

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Aprepitant Effects in Intravenous Heroin Dependence

Phase 1
Completed
Conditions
Opioid Dependence
Interventions
Drug: Placebo pill
Drug: Aprepitant
First Posted Date
2012-02-07
Last Posted Date
2021-08-23
Lead Sponsor
NYU Langone Health
Target Recruit Count
64
Registration Number
NCT01527994
Locations
🇺🇸

Bellevue Hospital Center & the NYU School of Medicine, New York, New York, United States

Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting

First Posted Date
2011-11-18
Last Posted Date
2013-12-03
Lead Sponsor
Sergio Bergese
Target Recruit Count
122
Registration Number
NCT01474915
Locations
🇺🇸

The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy